Andy Rawstron, David Cairns, Nichola Webster, Surita Dalal, Jane Shingles, Ruth de Tute, Anna Hockaday, Sharon Jackson, Sue Bell, Natasha Greatorex, David Stones, David Allsup, Adrian Bloor, Anita Sarma, Abraham Mullasseril Varghese, Talha Munir, Peter Hillmen. "Optimising MRD-guided treatment: UMRD4 as a half-way treatment timepoint for ibrutinib-venetoclax substantially delays MRD relapse after end of treatment in both IGHV-mutated and IGHV-unmutated CLL.." Blood, 2025. doi:10.1182/blood-2025-794